Regulators of IFN-gamma responses during Mycobacterium tuberculosis infection

结核分枝杆菌感染期间 IFN-γ 反应的调节因子

基本信息

  • 批准号:
    10659240
  • 负责人:
  • 金额:
    $ 52.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-06 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

Summary Tuberculosis (TB) is a leading cause of death by infectious disease worldwide. Current therapy requires at least six months of treatment and there is no effective vaccine that prevents pulmonary disease. There is a critical need to develop new therapies that will shorten treatment time and activate protective responses to prevent TB progression. Unfortunately, we continue to lack a fundamental understanding of the host immune pathways that protect against TB. While the cytokine interferon γ (IFNγ) is absolutely required, the precise mechanisms that drive IFNγ-mediated protection remain unclear. This is because IFNγ is a pleotropic mediator that controls both bacterial growth and the inflammatory response in the lungs, while bridging the innate and adaptive immune responses. To dissect the complex regulation of IFNγ responses, we conducted a genome-wide CRISPR Cas9 screens in macrophages to define the networks required for the IFNγ-mediated surface expression of MHCII. This screen uncovered an important role for the glycerol 3 kinase beta (GSK3b) in controlling IFNγ-dependent MHCII expression. Using chemical and genetic approaches coupled with transcriptome analysis we found that GSK3b and the paralog GSK3a contribute to the expression of a subset of IFNγ-inducible genes. Further mechanistic studies found that the loss of GSK3a/b blocks the ability of macrophages to serve as antigen presenting cells to CD4+ T cells ex vivo and results in dysregulated cytokine production by macrophages during M. tuberculosis infection. Thus, GSK3a/b balances the cellular response to IFNγ to protect against infection without driving inflammatory tissue damage. These data lead to the hypothesis that GSK3a/b is a critical mediator of the IFNγ response during TB in vivo. This proposal will use genetic approaches combined with in vivo models to dissect the role of GSK3a/b-mediated control of IFNγ responses and TB. Aim 1 will understand the mechanisms that regulate GSK3a/b control of IFNγ responses and determine how M. tuberculosis modulates GSK3a/b activity. In Aim 2, we will use unique models of bacterial control and inflammation to examine how the loss of myeloid-specific GSK3a and/or GSK3b disrupts the IFNγ-mediated control of M. tuberculosis growth and tissue damage. Finally, in Aim 3 we will use M. tuberculosis specific TCR-transgenic T cell mice to test the hypothesis that the loss of myeloid GSK3a and/or GSK3b results in reduced T cell responses and ineffective protection against TB. Together these aims will dissect the role of GSK3a/b in controlling IFNγ-responses and protecting against TB. These mechanisms can then be leveraged to develop new therapies that may shorten treatment times and prevent TB disease progression.
摘要 结核病(TB)是世界范围内主要的传染病死亡原因。目前的治疗方法至少需要六个 几个月的治疗,而且没有有效的疫苗来预防肺部疾病。迫切需要 开发新的治疗方法,缩短治疗时间并激活保护性反应,以防止结核病的进展。 不幸的是,我们仍然缺乏对宿主免疫途径的基本了解,这些免疫途径可以防止 结核病。虽然细胞因子干扰素γ(干扰素γ)是绝对必需的,但驱动干扰素γ介导的确切机制 保护措施仍不明朗。这是因为干扰素γ是一种多发性介质,它既控制细菌的生长,又控制 肺部的炎症反应,同时连接先天和获得性免疫反应。要仔细分析 干扰素γ反应的复杂调控,我们在巨噬细胞中进行了全基因组CRISPR Cas9筛选,以 确定干扰素γ介导的MHCII表面表达所需的网络。这个屏幕揭示了一个重要的 甘油3激酶β(GSK3b)在控制干扰素γ依赖的MHCII表达中的作用使用化学药品和 遗传方法结合转录组分析,我们发现GSK3b和Paralog GSK3a对 干扰素γ诱导基因亚集的表达。进一步的机制研究发现, GSK3a/b体外阻断巨噬细胞作为CD4+T细胞抗原提呈细胞的能力和结果 在结核分枝杆菌感染过程中巨噬细胞产生细胞因子的失调。因此,GSK3a/b平衡了 细胞对干扰素γ的反应,以防止感染,而不会导致炎症组织损伤。这些数据导致 假设GSK3a/b是体内结核病过程中干扰素γ反应的关键介质。这项提案将使用 遗传学方法结合体内模型剖析GSK3a/b介导的干扰素γ应答的调控作用 和肺结核。目标1将了解调节GSK3a/b控制干扰素γ反应的机制,并确定如何 结核分枝杆菌调节GSK3a/b的活性。在目标2中,我们将使用独特的细菌控制和炎症模型 研究髓系特异性GSK3a和/或GSK3b的缺失如何干扰干扰素γ介导的M。 肺结核的生长和组织损伤。最后,在目标3中,我们将使用结核分枝杆菌特异性TCR转基因T细胞 小鼠验证髓系GSK3a和/或GSK3b丢失导致T细胞反应减少和 对结核病的保护不力。这些目标将共同剖析GSK3a/b在控制干扰素γ反应中的作用 以及预防结核病。然后可以利用这些机制来开发新的疗法,这些疗法可能会缩短 治疗次数和防止结核病的进展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew Olive其他文献

Andrew Olive的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew Olive', 18)}}的其他基金

Genetic Mechanisms of Tissue-Resident Macrophage Maintenance and Function
组织驻留巨噬细胞维持和功能的遗传机制
  • 批准号:
    10651892
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
Mechanisms of MHCII expression and CD4+ T cell activation during Chlamydia trachomatis infection
沙眼衣原体感染过程中MHCII表达及CD4 T细胞活化机制
  • 批准号:
    9977431
  • 财政年份:
    2020
  • 资助金额:
    $ 52.4万
  • 项目类别:
Defining resistance and tolerance mechanisms in hyper-susceptible mice during M. tuberculosis infection
结核分枝杆菌感染期间高易感小鼠的抵抗和耐受机制的定义
  • 批准号:
    10092102
  • 财政年份:
    2020
  • 资助金额:
    $ 52.4万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 52.4万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 52.4万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 52.4万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 52.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 52.4万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 52.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了